AbbVie (NYSE:ABBV) Stock Rating Upgraded by Leerink Partnrs

AbbVie (NYSE:ABBV) was upgraded by research analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports. Leerink Partnrs also issued estimates for AbbVie’s FY2026 earnings at $13.69 EPS, FY2027 earnings at $15.36 EPS and FY2028 earnings at $16.79 EPS.

A number of other equities analysts have also weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of AbbVie to $195.00 and gave the stock a “buy” rating in a report on Tuesday. Guggenheim boosted their price objective on shares of AbbVie from $212.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Wolfe Research initiated coverage on shares of AbbVie in a research report on Friday, November 15th. They issued an “outperform” rating and a $205.00 target price for the company. Argus raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Citigroup cut their target price on shares of AbbVie from $226.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $203.50.

AbbVie Price Performance

ABBV stock opened at $176.94 on Friday. The firm has a 50 day moving average price of $189.47 and a 200-day moving average price of $181.04. AbbVie has a 52-week low of $137.65 and a 52-week high of $207.32. The firm has a market capitalization of $312.68 billion, a price-to-earnings ratio of 61.44, a PEG ratio of 2.03 and a beta of 0.63. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.92 by $0.08. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The company had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.28 billion. During the same period in the previous year, the business earned $2.95 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities research analysts forecast that AbbVie will post 10.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ABBV. Fairway Wealth LLC bought a new position in AbbVie in the 2nd quarter worth $26,000. Ridgewood Investments LLC bought a new position in AbbVie in the 2nd quarter worth $27,000. Groupama Asset Managment boosted its holdings in AbbVie by 40.3% in the 3rd quarter. Groupama Asset Managment now owns 135,749 shares of the company’s stock worth $27,000 after buying an additional 38,974 shares during the period. RPg Family Wealth Advisory LLC bought a new position in AbbVie in the 3rd quarter worth $28,000. Finally, Quest Partners LLC boosted its holdings in AbbVie by 4,140.0% in the 2nd quarter. Quest Partners LLC now owns 212 shares of the company’s stock worth $36,000 after buying an additional 207 shares during the period. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.